TSGH SAS has been Transgene’s reference shareholder since 1994. This financial holding company is a member of Institut Mérieux Group and is in fine owned by the Mérieux family and by the Christophe and Rodolphe Mérieux Foundation. Philippe Archinard is CEO of TSGH. Sandrine Flory has been TSGH’s permanent representative on Transgene’s Board of Directors… Continue reading Sandrine Flory TSGH
Category: tools-profils-members
Maya SAID
Maya Said has been an independent Director of Transgene since 2017. She brings more than 15 years of international experience in the healthcare industry. Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis, and Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D at Sanofi. Her… Continue reading Maya SAID
Alain MÉRIEUX
Alain Mérieux is Chairman of Institut Mérieux, a family holding company dedicated to medicine and public health worldwide. In 1963, Alain Mérieux founded bioMérieux, an in vitro diagnostics company. From 1968 to 1994, he was Chairman of Institut Mérieux, which specialized in human and veterinary vaccines, before divesting the vaccine business. In 1994, he created… Continue reading Alain MÉRIEUX
Marie LANDEL
Marie Landel founded Marie Landel & associates, now Axelia Partners, a consultancy based in Cambridge (Massachusetts) specialized in advising European companies on the creation and development of US subsidiaries. She has significant experience supporting French and European biotechnology companies in the United States. With more than 30 years of practice, she has built an extensive… Continue reading Marie LANDEL
Benoît HABERT
Benoît Habert is Executive Vice President and Director of the Marcel Dassault Industrial Group and is a board member of several listed and private companies. He holds an MBA from INSEAD and a Master of Business Law. Benoît Habert has been a Director of the Company since 2000. Committees: member of the Compensation Committee and… Continue reading Benoît HABERT
Jean-Luc BÉLINGARD
Jean-Luc Bélingard was Chairman and Chief Executive Officer of bioMérieux S.A from 2010 to 2017. He graduated from the Ecole des Hautes Etudes Commerciales (HEC) of Paris (1971) and holds a Master of Business Administration (MBA) from Cornell University, US (1974). Since then, he has held management positions at Merck, Sharp and Dohme (1974-1983), Roche… Continue reading Jean-Luc BÉLINGARD
Emmanuelle QUILES
Emmanuelle Quilès is a seasoned pharmaceutical industry executive with deep expertise in global strategy, operations, and innovation. Until recently, she served as Worldwide Vice President for Cardiovascular, Metabolism, and Pulmonary Hypertension at Janssen Global Commercial Strategy Organization (Johnson & Johnson) and previously held senior leadership positions at Wyeth, Pfizer, and her own biotech start-up Harmonium.… Continue reading Emmanuelle QUILES
Christelle Schwoerer
Christelle Schwoerer has served as VP Human Resources since 2024. She joined Transgene’s Human Resources department in December 2013 as a Human Resources Assistant, after initial experience in construction and industry. Her various roles at Transgene have enabled her to develop generalist skills in human resources and to contribute to projects of major importance to… Continue reading Christelle Schwoerer
John FELITTI
John Felitti has served Transgene as General Counsel & Corporate Secretary since 2016. Before joining Transgene, he was Associate Vice President, Corporate Law, Finance & Securities Law at Sanofi and previously held other positions in the Sanofi and the Aventis legal departments. From 1996 to 2003, he was an associate attorney at the Paris offices… Continue reading John FELITTI
James Wentworth, PhD
James Wentworth, PhD, has serve as Chief Business Officer since 2024. Dr. Wentworth is responsible for developing, leading, and implementing Transgene’s business, corporate development and partnering strategies. He has over 15 years of experience working in the pharma and biotech industry. James was Director, Business Development and Strategy at Adaptimmune, a NASDAQ-listed biotechnology company focused… Continue reading James Wentworth, PhD